Overview

Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)

Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the long term safety and efficacy of GSP 301 NS compared to 2 placebo NS formulations for the treatment of perennial allergic rhinitis (subjects 12 years of age and older)
Phase:
Phase 3
Details
Lead Sponsor:
Glenmark Specialty S.A.